Synergistic effects of childhood adversity and polygenic risk in first-episode psychosis: the EU-GEI study.

Childhood trauma first-episode psychosis interaction contrast ratio polygenic risk schizophrenia synergistic effects

Journal

Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142

Informations de publication

Date de publication:
04 2023
Historique:
medline: 15 6 2023
pubmed: 13 6 2023
entrez: 13 6 2023
Statut: ppublish

Résumé

A history of childhood adversity is associated with psychotic disorder, with an increase in risk according to the number of exposures. However, it is not known why only some exposed individuals go on to develop psychosis. One possibility is pre-existing polygenic vulnerability. Here, we investigated, in the largest sample of first-episode psychosis (FEP) cases to date, whether childhood adversity and high polygenic risk scores for schizophrenia (SZ-PRS) combine synergistically to increase the risk of psychosis, over and above the effect of each alone. We assigned a schizophrenia-polygenic risk score (SZ-PRS), calculated from the Psychiatric Genomics Consortium (PGC2), to all participants in a sample of 384 FEP patients and 690 controls from the case-control component of the EU-GEI study. Only participants of European ancestry were included in the study. A history of childhood adversity was collected using the Childhood Trauma Questionnaire (CTQ). Synergistic effects were estimated using the interaction contrast ratio (ICR) [odds ratio (OR) There was some evidence that the combined effect of childhood adversities and polygenic risk was greater than the sum of each alone, as indicated by an ICR greater than zero [i.e. ICR 1.28, 95% confidence interval (CI) -1.29 to 3.85]. Examining subtypes of childhood adversities, the strongest synergetic effect was observed for physical abuse (ICR 6.25, 95% CI -6.25 to 20.88). Our findings suggest possible synergistic effects of genetic liability and childhood adversity experiences in the onset of FEP, but larger samples are needed to increase precision of estimates.

Sections du résumé

BACKGROUND
A history of childhood adversity is associated with psychotic disorder, with an increase in risk according to the number of exposures. However, it is not known why only some exposed individuals go on to develop psychosis. One possibility is pre-existing polygenic vulnerability. Here, we investigated, in the largest sample of first-episode psychosis (FEP) cases to date, whether childhood adversity and high polygenic risk scores for schizophrenia (SZ-PRS) combine synergistically to increase the risk of psychosis, over and above the effect of each alone.
METHODS
We assigned a schizophrenia-polygenic risk score (SZ-PRS), calculated from the Psychiatric Genomics Consortium (PGC2), to all participants in a sample of 384 FEP patients and 690 controls from the case-control component of the EU-GEI study. Only participants of European ancestry were included in the study. A history of childhood adversity was collected using the Childhood Trauma Questionnaire (CTQ). Synergistic effects were estimated using the interaction contrast ratio (ICR) [odds ratio (OR)
RESULTS
There was some evidence that the combined effect of childhood adversities and polygenic risk was greater than the sum of each alone, as indicated by an ICR greater than zero [i.e. ICR 1.28, 95% confidence interval (CI) -1.29 to 3.85]. Examining subtypes of childhood adversities, the strongest synergetic effect was observed for physical abuse (ICR 6.25, 95% CI -6.25 to 20.88).
CONCLUSIONS
Our findings suggest possible synergistic effects of genetic liability and childhood adversity experiences in the onset of FEP, but larger samples are needed to increase precision of estimates.

Identifiants

pubmed: 37310339
doi: 10.1017/S0033291721003664
pii: S0033291721003664
pmc: PMC10106300
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1970-1978

Subventions

Organisme : Medical Research Council
ID : MR/S003444/1
Pays : United Kingdom

Références

JAMA Psychiatry. 2019 Jan 1;76(1):79-86
pubmed: 30477014
Arch Gen Psychiatry. 1991 Aug;48(8):764-70
pubmed: 1883262
Med Hypotheses. 2014 Sep;83(3):276-81
pubmed: 24957505
PLoS Genet. 2013 Mar;9(3):e1003348
pubmed: 23555274
JAMA Psychiatry. 2019 Jun 1;76(6):584-593
pubmed: 30892562
Schizophr Res. 2019 Nov;213:65-71
pubmed: 30660575
Schizophr Res. 2019 Mar;205:51-57
pubmed: 29653893
Am J Psychiatry. 1994 Aug;151(8):1132-6
pubmed: 8037246
Lancet Psychiatry. 2019 May;6(5):427-436
pubmed: 30902669
Soc Psychiatry Psychiatr Epidemiol. 2002 Jul;37(7):329-35
pubmed: 12111025
Schizophr Bull. 2012 Jun;38(4):661-71
pubmed: 22461484
Schizophr Res. 2016 Oct;176(2-3):171-176
pubmed: 27344984
Acta Psychiatr Scand. 2014 Oct;130(4):311-7
pubmed: 24961959
Soc Psychiatry Psychiatr Epidemiol. 2020 May;55(5):645-657
pubmed: 31974809
Front Psychol. 2017 Aug 24;8:1276
pubmed: 28883800
Schizophr Res. 2013 Nov;150(2-3):356-65
pubmed: 24094883
Int J Epidemiol. 2007 Oct;36(5):1111-8
pubmed: 17726040
Biol Psychiatry. 2017 Mar 15;81(6):470-477
pubmed: 27765268
Epidemiology. 1992 Sep;3(5):452-6
pubmed: 1391139
Psychol Med. 2019 Jun;49(8):1378-1391
pubmed: 30282569
World Psychiatry. 2019 Jun;18(2):173-182
pubmed: 31059627
Schizophr Res. 2019 Mar;205:58-62
pubmed: 29793818
J Psychiatr Res. 2014 Dec;59:14-21
pubmed: 25246365
J Psychiatr Res. 2018 Jan;96:57-64
pubmed: 28965006
Nature. 2014 Jul 24;511(7510):421-7
pubmed: 25056061
Biol Psychiatry. 2002 Oct 15;52(8):843; author reply 843-5
pubmed: 12372656
Schizophr Res. 2005 Nov 1;79(1):59-68
pubmed: 16005191
Br J Psychiatry. 2014 Aug;205(2):113-9
pubmed: 24925986
Am J Psychiatry. 2019 Oct 1;176(10):846-855
pubmed: 31416338
J Child Psychol Psychiatry. 2016 Oct;57(10):1103-12
pubmed: 27647050
JAMA Psychiatry. 2018 Jan 1;75(1):36-46
pubmed: 29214289
Int J Bipolar Disord. 2016 Dec;4(1):2
pubmed: 26763504
Schizophr Bull. 2008 Jan;34(1):193-9
pubmed: 17586579
Psychol Med. 2016 Mar;46(4):759-70
pubmed: 26526099
Bipolar Disord. 2020 Mar;22(2):174-181
pubmed: 31628696
Schizophr Bull. 2018 Oct 17;44(6):1195-1203
pubmed: 29762765
Lancet. 2014 May 10;383(9929):1677-1687
pubmed: 24315522
Biol Psychiatry. 2018 Mar 15;83(6):492-498
pubmed: 28987712
Genome Med. 2017 Nov 13;9(1):96
pubmed: 29132412
Int J Epidemiol. 2012 Apr;41(2):514-20
pubmed: 22253321
Nature. 2009 Aug 6;460(7256):748-52
pubmed: 19571811
Eur Arch Psychiatry Clin Neurosci. 2017 Feb;267(1):1-2
pubmed: 28070643
Biol Psychiatry. 2018 Jul 15;84(2):138-147
pubmed: 29129318
Psychol Med. 2007 Oct;37(10):1377-91
pubmed: 17335638
Can J Psychiatry. 2013 Jan;58(1):44-51
pubmed: 23327756
Neurosci Biobehav Rev. 2017 Feb;73:191-218
pubmed: 27993603
Child Abuse Negl. 2001 Sep;25(9):1177-200
pubmed: 11700691
PLoS One. 2016 Sep 20;11(9):e0163319
pubmed: 27648571
Nat Genet. 2019 Jul;51(7):1193
pubmed: 31160808
Psychol Rev. 1997 Oct;104(4):667-85
pubmed: 9337628
Brain Res. 1990 Jun 25;521(1-2):311-5
pubmed: 2119850

Auteurs

Monica Aas (M)

Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London SE5 8AF, UK.
Norment, Oslo University Hospital, Oslo, Norway.

Luis Alameda (L)

Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London SE5 8AF, UK.
Service of General Psychiatry, Treatment and Early Intervention in Psychosis Program, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Instituto de Investigación Biomédica de Sevilla, Universidad de Sevilla, Seville, Spain.
Department of Psychiatry, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Sevilla, Spain.

Marta Di Forti (M)

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AE, UK.

Diego Quattrone (D)

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AE, UK.

Paola Dazzan (P)

Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London SE5 8AF, UK.

Antonella Trotta (A)

Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London SE5 8AF, UK.

Laura Ferraro (L)

Biomedicine, Neuroscience and Advanced Diagnostic (BiND) Department, University of Palermo, Palermo, Italy.

Victoria Rodriguez (V)

Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London SE5 8AF, UK.

Evangelos Vassos (E)

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AE, UK.

Pak Sham (P)

Department of Psychiatry, University of Hong Kong, Pok Fu Lam, Hong Kong.

Giada Tripoli (G)

Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London SE5 8AF, UK.
Biomedicine, Neuroscience and Advanced Diagnostic (BiND) Department, University of Palermo, Palermo, Italy.

Caterina La Cascia (C)

Biomedicine, Neuroscience and Advanced Diagnostic (BiND) Department, University of Palermo, Palermo, Italy.

Daniele La Barbera (D)

Biomedicine, Neuroscience and Advanced Diagnostic (BiND) Department, University of Palermo, Palermo, Italy.

Ilaria Tarricone (I)

Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, 40126 Bologna, Italy.

Roberto Muratori (R)

Department of Mental Health and Pathological Addiction, Bologna Local Health Authority, Bologna, Italy.

Domenico Berardi (D)

Department of Biomedical and Neuro-motor Sciences, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, 40126 Bologna, Italy.

Antonio Lasalvia (A)

Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Piazzale L.A. Scuro 10, 37134 Verona, Italy.

Sarah Tosato (S)

Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Piazzale L.A. Scuro 10, 37134 Verona, Italy.

Andrei Szöke (A)

INSERM U955, Equipe 15, Institut National de la Santé et de la Recherche Médicale, 94010 Créteil, France.

Pierre-Michel Llorca (PM)

CMPB CHU Clermont-Ferrand, EA 7280, University Clermont Auvergne, Clermont-Ferrand, France.

Celso Arango (C)

Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM (CIBERSAM), 28007 Madrid, Spain.

Andrea Tortelli (A)

Etablissement Public de Santé Maison Blanche, 75020 Paris, France.

Lieuwe de Haan (L)

Department of Psychiatry, Early Psychosis Section, Amsterdam UMC, Location: Academic Medical Centre, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.

Eva Velthorst (E)

Department of Psychiatry, Early Psychosis Section, Amsterdam UMC, Location: Academic Medical Centre, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Department of Psychiatry, Icahn School of Medicine, Mount Sinai, NY, USA.

Julio Bobes (J)

Faculty of Medicine and Health Sciences - Psychiatry, Universidad de Oviedo, ISPA, INEUROPA, CIBERSAM, 33006 Oviedo, Spain.

Miguel Bernardo (M)

Barcelona Clinic Schizophrenia Unit, Hospital Clinic of Barcelona, University of Barcelona; IDIBAPS, CIBERSAM, 08036 Barcelona, Spain.

Julio Sanjuán (J)

Department of Psychiatry, School of Medicine, Universidad de Valencia, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), 46010 Valencia, Spain.

Jose Luis Santos (JL)

Department of Psychiatry, Servicio de Psiquiatría Hospital 'Virgen de la Luz', 16002 Cuenca, Spain.

Manuel Arrojo (M)

Department of Psychiatry, Psychiatry Genetic Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Complejo Hospitalario Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Spain.

Cristina Marta Del-Ben (CM)

Division of Psychiatry, Department of Neuroscience and Behaviour, Ribeirão Preto Medical School, University of São Paulo, São Paulo 14049-900, Brazil.

Paulo Rossi Menezes (PR)

Department of Preventative Medicine, Faculdade de Medicina FMUSP, University of São Paulo, São Paulo 01246-903, Brazil.

Jean-Paul Selten (JP)

Rivierduinen Institute for Mental Health Care, 2333 ZZ Leiden, The Netherlands.

Peter B Jones (PB)

Department of Psychiatry, University of Cambridge, Cambridge CB2 0SZ, UK.

Hannah E Jongsma (HE)

Psylife Group, Division of Psychiatry, University College London, London W1T 7NF, UK.

James B Kirkbride (JB)

Psylife Group, Division of Psychiatry, University College London, London W1T 7NF, UK.

Bart P F Rutten (BPF)

Department of Psychiatry and Neuropsychology, School of Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, 6200 MD Maastricht, The Netherlands.

Jim van Os (J)

Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London SE5 8AF, UK.
Department of Psychiatry and Neuropsychology, School of Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, 6200 MD Maastricht, The Netherlands.

Charlotte Gayer-Anderson (C)

Health Service and Population Research, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London SE5 8AF, UK.

Robin M Murray (RM)

Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London SE5 8AF, UK.

Craig Morgan (C)

Health Service and Population Research, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London SE5 8AF, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH